A “Just Transition” for Drug-Resistant Tuberculosis | Public Humanities | Cambridge Core A “Just Transition” for Drug-Resistant Tuberculosis - Volume 1

Person‑centred TB care is holistic, individualized, respectful and empowering.
A new KNCV publication argues this shift is only the start of a just transition for DR‑TB, urging us to ask: Who sets the agenda? Who benefits? And who is left behind?
#TBSky #TB #DRTB @universitypress.cambridge.org

An assessment of video-observed treatment as an adherence support tool for patients with drug-resistant TB In 2017, WHO endorsed digital adherence technologies, including video-observed treatment (VOT), to support TB treatment adherence. In 2021, Eswatini implemented VOT to support adherence for…

🚨 Publication Alert🚨
WHO has endorsed tools like VOT for TB. Eswatini implemented VOT for #DRTB patients, despite limited evidence of feasibility in low-resource environments. VOT is feasible and acceptable in Eswatini, but more research is needed. buff.ly/vYti3vZ
Congrats to all contributors👏

Researcher Tuberculosis More than 500 staff members at the Institute of Tropical Medicine (ITM) contribute every day to improving the health of millions of people world...

Come join us! Researcher TB (MD/PhD)
Dept of Clinical Sciences www.itg.be/en/jobs-and-... #TBfighters #tbsky #CAD #AMR #DRTB #tuberculosis #IDSky #EndTB

Tuberculosis doesn't respect borders Tuberculosis kills 1.3 million people each year, making it the deadliest infectious disease in the world, write KJ Seung and Kunda Kwabisha Mikanda. Eliminating U.S. funding to combat it around the…

Drug-resistant TB. Doesn’t. Stop. At. Borders.
Cuts to global funding put lives at risk.
Read more via @wbur.org ⬇️
www.wbur.org/cognoscenti/...
#DRTB #GlobalHealth #HealthJustice #CareCantWait

Treatment Action Group – TAG Community Resources 2025 – ASCENT DR-TB

Breaking News🗞️

On Monday 31 of March 2025, the #ASCENTDRTB Consortium Partner @treatmentactiongroup.org launched the update of community materials on #DRTB and a brand-new activists’ guide to shorter treatment for DR-TB.💫

🔗Learn more here: ascentdrtb.org/treatment-ac...
#TBSky #IDSky

Miss part one of the #DRTB lecture series? Join us at the TB GAPS ECHOHub on Thursday, 27 March, for part two!

Register here: buff.ly/jQVfK7m

Join us at the TB GAPS ECHOHub on Thurs, 13 March, for part one of a lecture series on #DRTB, presented by Dr Jennifer Furin, who will share knowledge and experiences on best practices for clinical management to prevent and treat DRTB in patients.
Register here: buff.ly/jQVfK7m
#TBSky

Kicking off #TB #JournalClub 2025 with great discussion of shorturl.at/AGD8l Duong &al 2024 meta-analysis of VQUIN & TB-CHAMP RCTs. In our closing poll, 54% of audience members would take levo TPT if their household contact had quinolone-sensitive #DRTB - the rest chose another regimen/no TPT #tbsky

Empowering people affected by tuberculosis The extension of the ASCENT project, also known as ASCENT DR-TB project, is dedicated to leveraging the knowledge and expertise of consortium partners and global forums to rethink optimal care for TB

From 2019-2023, the @unitaidngos.bsky.social funded #ASCENT project supported 19K+ people across 5 countries with #DigitalAdherenceTechnologies (DATs) for #TB treatment. 📲

Now, #ASCENTDRTB is working with 8 countries to accelerate access and scale up 🚀shorter, effective regimens for #DRTB. 💊
👇 #ID

Introducing BPaL: Experiences from countries supported under the LIFT-TB project Background Previously, drug-resistant tuberculosis (DR-TB) patients were treated with long, toxic, and relatively ineffective regimens. However, in recent years, there have been major improvements mad...

When @who.int recommended the use of a 6-months all-oral #BPaL (bedaquiline, pretomanid and linezolid) regimen under #OperationalResearch conditions for selected people with #DrugResistant #tuberculosis ( #DRTB) in 2020, we took action.

Read our recent publication: journals.plos.org/plosone/arti...

Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, ... Both of the bedaquiline-containing regimens maintained superiority to the control regimen, without evidence of increased mortality, providing two additional evidence-based treatment options for patien...

❗Final #TBJC of 2024
🕓Thurs November 28, 4pm UK
🏛️Hosts: SGUL. Chair: Sean Wasserman. Presenter: Sharenja Ratnakumar.
💊 shorturl.at/jcijg long-term efficacy & safety from STREAM2 trial of shorter regimens for #DRTB
✉️ eepurl.com/hO4D79 to join mailing list for monthly #tuberculosis journal clubs!

Trial shows exciting new TB oral regimen is safe and effective A groundbreaking initiative known as BEAT Tuberculosis has become the world's first initiative in the fight against drug-resistant tuberculosis (DR-TB) for all population groups, influencing the World...

[DailyRead] A new #TB pill just cleared a South African trial, showing it’s safe, effective, and could change the game in treating the disease. #DRTB #BEATtuberculosis #SouthAfrica www.timeslive.co.za/news/south-a...